Latest Conference Articles

ACOG 2026: James A. Simon, MD, discusses what the results mean for frontline clinician confidence in prescribing the non-hormonal VMS treatment.

Late-breaking data presented at ACOG 2026 showed GLP-1 RA exposure before or during early pregnancy was not associated with hypertensive disorders of pregnancy.

ACOG 2026: Jill Liss, MD, details how primary care physicians can safely initiate hormone therapy, manage menopause counseling in brief visits, and more.

ACOG 2026: The new guidance formally introduces clinician-ordered self-collected HPV testing as an option for cervical cancer screening.

ACOG 2026: Genevieve Neal-Perry, MD, discussed her clinical experience with elinzanetant for the treatment of VMS associated with menopause.

A nationally representative study found 71.5% of US women aged 21-49 years were open to HPV self-collection, including 9.7 million who were underscreened or never screened.

Hear from the presenting investigator of late-breaking research presented at ACOG 2026 that found over 80% of pregnancy-related infection deaths were preventable.

Hot flashes and night sweats are just 2 of the myriad symptoms associated with menopause. Click through a quick refresher on the transition and effective treatments.

ACOG 2026: In a nationally representative survey, 75% of women with menopausal symptoms reported sleep problems vs 49.8% without symptoms.

New research shows 35.3% of insured individuals with hypertensive disorders of pregnancy had a preventive care visit within 12 months postpartum.

Details on 11 key abstracts with clinical relevance for primary care, from menopause management to cervical cancer screening.

New evidence suggests lowering LDL-C to 44 mg/dL with PCSK9 therapy may better protect high-risk patients with diabetes, aligning primary prevention targets with secondary prevention.

Phase 3b findings suggest that combining a GLP-1/GIP receptor agonist with IL-17 inhibition may improve both joint and metabolic outcomes in adults with psoriatic arthritis and obesity.

ACC 2026: A new secondary analysis of the VESALIUS-CV study shows evolocumab cuts heart attacks, strokes and deaths in high‑risk patients with type 2 diabetes.

ACC 2026. Evolocumab reduced first CV events by 31% in high-risk diabetes without ASCVD, supporting earlier LDL-C intensification.

New 4-year data from the ADlong trial show lebrikizumab achieved EASI-75 in 94% of atopic dermatitis patients on once-monthly maintenance dosing.

Five trials presented at AAAAI 2026 highlight new therapies and prevention strategies for hereditary angioedema, atopic dermatitis, asthma, and chronic urticaria.

ATS: Replace race-based PFTs with race-neutral GLI Global equations to improve clinical equity and accuracy.

NIAID/NIH immunotherapy uses measured Peanut Butter to raise allergy thresholds, with specialist-guided dosing and safety nuances.

Highlights include widespread lack of structured menopause education in primary care residency programs, sleep benefits of elinzanetant, and more.

Cochrane shares her own research findings on how clinician specialty shapes menopause care and highlights gaps in hormone therapy prescribing.

TMS: Harvard's Caroline Mitchell, MD, MPH, questions the direction of genitourinary syndrome research priorities and reflects on FDA's removal of HRT warnings.

Study author Daniel Jiang, MD, PhD, discusses data linking hormone therapy to increased autoimmune disease risk in postmenopausal women and clinical implications.

Harvard's Caroline Mitchell, MD, MPH, explains how common OTC products can worsen vulvovaginal symptoms and the importance of a targeted history in GSM care.

Donna Plecha, MD, discusses how AI-powered mammography risk prediction and polygenic risk scores will enable personalized breast cancer screening within the next decade.

Breast imaging expert, Donna Plecha, MD, provides a roadmap for primary care physicians to implement risk assessment tools and high-risk clinic referrals in their practice.

Access, cost, and clinician awareness remain significant barriers to implementing supplemental breast screening, according to Plecha.

Breast imaging expert Donna M. Plecha, MD, explains the FDA's dense breast notification requirement and when to recommend supplemental MRI screening.

Mitchell highlights hormone therapy prescribing for primary care: treatment algorithms, vaginal estrogen safety, and when progestins aren't needed.

TMS 2025: Katrina Wugalter, MA, discusses research showing that age—not menopause stage—drives brain volume decline, and how lifestyle factors can help preserve brain health in midlife women.